InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

NewsGuard 100/100 Score
Jun 18 2010

InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

Dr. Alex DePaoli, Acting Chief Medical Officer of InteKrin Therapeutics, will present "INT131 Besylate, a Selective PPAR-gamma Modulator (SPPARM), Improved Glycemic Control in Patients with Type 2 Diabetes without Causing the Edema Seen with Pioglitazone."

SOURCE InteKrin Therapeutics Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

Study shows daily glucose levels fluctuate more than we thought, challenging diabetes diagnosis
Childhood sedentariness associated with increase in blood insulin concentration, study shows
Healthy eating, physical activity, and medication: Type 2 diabetes patients' willingness to engage varies
Popular diabetes drugs not linked to thyroid cancer risk, study finds
Exercise shown to curb appetite in diabetes and prediabetes patients
Statins slightly up diabetes risk but cardiovascular benefits remain, finds study
Restoring insulin sensitivity without TZD side effects
Moderate vitamin E, C, and β-carotene intake reduces type 2 diabetes risk

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Heavy alcohol use linked to increased risk of Type 2 diabetes in middle-aged adults